Sponsors List
We would like to thank our Sponsors and Exhibitors for their commitment & support and look forward to future collaborations.
Our Exhibitors welcome you at the exhibition area.
Status as of October 2023
Gold Plus Sponsor
ITM Isotope Technologies Munich SE
Germany
ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our nearly two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life.
Gold Sponsor
Novartis Pharma AG
Switzerland
Novartis is reimagining medicine to improve and extend people’s lives. We deliver high-value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. About 108,000 people of more than 140 nationalities work together to bring Novartis products to nearly 800 million people around the world.
© 2023 Novartis Pharma AG | CH-4002, Basel, Switzerland
Contact:
Address: Novartis Pharma AG, Forum 1, Novartis Campus, CH-4002, Basel, Switzerland
Tel: +41 61 324 11 11
Email: infomed@adacap.com
Social media:
Novartis (@Novartis) / Twitter
Novartis | LinkedIn
Silver Sponsors
Hermes Medical Solutions
Sweden
Since its establishment in 1976 in Stockholm, Sweden, Hermes Medical Solutions has continuously innovated to enable faster and more personalized diagnosis and therapies in molecular imaging and theranostics.
The company was the first to develop SPECT reconstruction software and dual-head whole-body scanning, and the first to introduce medical image fusion software for combined viewing of images from different scanners. We empower healthcare professionals by providing state-of-the-art software for all clinical scenarios in ONE vendor-neutral platform: Hermia.
Our mission is to combine innovation leadership in nuclear medicine/molecular imaging software with customer-driven service, and our success lies in our close and longstanding collaboration with our customers to meet their software, support and service needs.
The result is improved quality in patient management and decision support that benefits thousands of healthcare providers and their patients worldwide.
MONROL NUCLEAR PRODUCTS
Turkey
Monrol is one of the world’s largest nuclear medicine companies leading innovation for the development and manufacturing of GMP grade radioisotopes and radiopharmaceuticals having headquarters in Istanbul. Monrol is distributing its world-class radiopharmaceutical products portfolio with excellence in global markets. Monrol is a CDMO, providing early development support to its customers as well as offering fully integrated services for today’s nimble, lean, virtual companies effectively taking new product concepts into clinical trials, demonstrating proof of concept and going into first-in-human studies. Monrol is committed to transform and improve patient journey in cancer treatment with its radiopharmaceutical products portfolio distributing to more than 60 countries around the globe. To learn more, visit www.monrol.com and LinkedIn (https://www.linkedin.com/company/eczac-ba--monrol-n-kleer-r-nler/).
POINT Biopharma
United States of America
POINT Biopharma is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT aims to transform precision medicine by combining a portfolio of targeted radioligand assets, a seasoned management team, an industry-leading pipeline, in-house manufacturing capabilities, and secured supply for medical isotopes including actinium-225 and lutetium-177. POINT’s active clinical trials include FRONTIER, a phase 1 trial for PNT2004, a pan-cancer program targeting fibroblast activation protein-α (FAP-α), and SPLASH, the phase 3 trial for PNT2002 for people with metastatic castration resistant prostate cancer (mCRPC) after second-line hormonal treatment. Learn more about POINT Biopharma at https://www.pointbiopharma.com/.
Siemens Healthineers
Germany
At Siemens Healthineers, we pioneer breakthroughs in healthcare. For everyone. Everywhere. By constantly bringing breakthrough innovations to market, we enable healthcare professionals to deliver high-quality care, leading to the best possible outcome for patients.
Our portfolio, spanning from in-vitro and in-vivo diagnostics to image-guided therapy and innovative cancer care, is crucial for clinical decision-making and treatment pathways. With our strengths in patient twinning, precision therapy, as well as digital, data, and artificial intelligence (AI), we are well positioned to take on the biggest challenges in healthcare. We will continue to build on these strengths to help fight the world’s most threatening diseases, improving the quality of outcomes, and enabling access to care.
We are a team of 66,000 highly dedicated employees across more than 70 countries passionately pushing the boundaries of what’s possible in healthcare to help improve people’s lives around the world.
Telix Pharmaceuticals Limited
Belgium
Telix is a global commercial-stage biopharmaceutical company focused on the development of therapeutic and diagnostic radiopharmaceuticals, and a service provider in nuclear medicine, with its European headquarters located in Liège, Belgium.
Telix’s targeted radiation imaging and therapy technologies have potential to transform the way clinicians can find and manage cancer and rare diseases, to inform treatment decisions and deliver personalised therapy in areas of major unmet medical need.
With more than 20 clinical studies underway worldwide, Telix’s core pipeline is focused on prostate, kidney, brain, and blood cancers as well as a range of hard to treat immunologic and rare diseases.
Telix has received regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the U.S. Food and Drug Administration (FDA), Health Canada for its prostate cancer imaging agent (Illuccix®, TLX591-CDx, kit for the preparation of 68Ga-PSMA-11 injection) and is progressing marketing authorisation applications for TLX591-CDx in the EU and the UK.
TRASIS
Belgium
At Trasis we are dedicated to helping the medical community access new radio-labelled therapeutic and diagnostic substances easily and faster.
To this end, we design, manufacture, sell and support high performance synthesizers (AllinOne and AllinOne mini), dose preparation equipment (Unidose and Quickfill dispensers), their shielding and accessories. We also develop customized synthetic methods and instruments. We can provide GMP Active Pharmaceutical Ingredients (API) and assist our customers with their regulatory affairs.
Our proven radiopharmaceutical expertise, coupled with our high-end instruments, allow us to provide fully integrated solutions for an effective tracer production and faster transition from drug development to marketing authorization.
Bronze Sponsors
Bayer AG
Germany
Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With our innovative products, we are contributing to finding solutions to some of the major challenges of our time.
CheMatech
France
CheMatech is a unique company in Europe specializing in the design and production of chelators (DOTA, NOTA derivatives) for Nuclear Medicine and Molecular Imaging. These molecules are used for the radiolabeling of biovectors such as peptides or antibodies. CheMatech provides its clients with a catalog of chelators suitable for most radiometals used for PET, SPECT or therapy and also offers custom syntheses, from the design of the chelator to the production in bulk. CheMatech is able to produce cGMP chelators, and related molecules, for the production of APIs from gram to kilogram scale.
OncoBeta GmbH
Germany
OncoBeta GmbH is an international medical device company specialized in innovative therapies for the treatment of non-melanoma skin cancer. Its flagship product, the Rhenium-SCT® (Skin Cancer Therapy), uses the radioactive isotope Rhenium-188 to precisely target NMSC while minimizing damage to healthy tissue. OncoBeta is dedicated to providing effective, non-invasive and painless treatments that improve quality of life.
PanTera nv
Belgium
PanTera will allow cancer patients worldwide to benefit from Actinium-225 in therapeutic radiopharmaceuticals by making the radioisotope available in large quantities for approved drugs from 2028 onward, while supporting clinical trials and research by supplying small quantities of 225Ac from 2024 onward. The Early Supply will be assured on the basis of Thorium-229 decay and will allow to supply 1-2 Curies per year. Our industrial production process is based on transforming Radium-226 into high purity Actinium-225 by gamma irradiation and can provide >100Ci/y to the future market. In this way, PanTera supports development of the next generation cancer treatments, fostering a future where personalized nuclear medicine is the norm.
Voximetry
United States
Voximetry is a software and services company committed to advancing Dosimetry-Guided Radiopharmaceutical Therapy (DG-RPT). With Torch® we aim to improve patient outcomes by moving beyond population-based models and making it simpler for clinicians to develop patient-specific RPT treatment options. As the industry accuracy leader, Torch® provides the only GPU-accelerated full Monte Carlo Dose Calculation, including voxel-level corrections for density. The result is an extremely accurate dose assessment in seconds. Voximetry also offers a comprehensive range of Professional Services, with unmatched expertise and tools, which includes project management to expedite implementation and support for clinical trials, pre-clinical studies, and research.
Basis Sponsor
ARTBIO INC
USA
CMR
Germany
Curium
France
DSD Pharma GmbH
Austria
DSD Pharma is a GDP-certified distributor of pharmaceuticals, radiopharmaceuticals and medical products, and medical-technical equipment in the field of nuclear medicine and radiopharmacy.
Nuvia
France
SOFIE
United States
The Oncidium foundation F.U.P.
United States
The Oncidium foundation is dedicated to support and accelerate the development of radiotheranostics (RLT) for cancer care. Our activities are based on 3 pillars:
ACCESS through a wide network of ambassador experts and a worldwide map of therapy centers.
EDUCATION & awareness are essential, as they help to bring a better understanding of the functioning & benefits of RLT, still unknown to some practitioners & the general public.
HOPE - The foundation is evaluating all possibilities to support clinical developments of efficient RLT & individual cases to reduce treatment overall costs in low-income countries.
Come & meet us!
WARMTH
United States
The "World Association of Radiopharmaceutical and Molecular Therapy" (WARMTH) extends its activities worldwide. WARMTH is the only worldwide organization founded to promote the use of radionuclide molecular therapy and of the relatively novel paradigm of ‘Theragnostics.’
WARMTH is a voluntary non-profit organization of individuals specifically associated for the purposes and for using the means, to achieve the following research and educational objectives: Join us in Muscat, Oman, for the 19th ICRT from the 8th to the 12th of February.
Come by our table to learn more about membership or to help us design a clinical trial finder tool for radiopharmaceutical trials.
